1578-96-7

Basic information

• Product Name: (1-METHYL-1H-INDAZOL-3-YL)METHANOL
• Synonyms: (1-METHYL-1H-INDAZOL-3-YL)METHANOL;(1-Methyl-1H-indazol-3-yl)methanol 97%;(1H-indazol-3-yl)Methanol;3-(Hydroxymethyl)-1-methyl-1H-indazole 97%;3-(HydroxyMethyl)-1-Methyl-1H-indazole;(1-Methyl-1H-indazol-3-yl)
• CAS NO: 1578-96-7
• Molecular Formula: C9H10N2O
• Molecular Weight: 162.19
• Mol File: 1578-96-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 128
• Flash Point: 154.791 °C
• Appearance: /
• Density: 1.226 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.622
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (1-METHYL-1H-INDAZOL-3-YL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (1-METHYL-1H-INDAZOL-3-YL)METHANOL(1578-96-7)
• EPA Substance Registry System: (1-METHYL-1H-INDAZOL-3-YL)METHANOL(1578-96-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 1578-96-7(Hazardous Substances Data)

Usage

General Description

(1-Methyl-1H-indazol-3-yl)methanol is a synthetic compound and belongs to the class of organic compounds known as indazoles, which are aromatic heterocyclic compounds containing a pyrazole ring fused to a benzene ring. It is characterized by a 1H-indazole moiety, where a hydrogen atom at the third position is replaced by a methanol group, and the nitrogen atom at the first position is substituted by a methyl group. While there is not much information available on its properties or uses, it is typically involved in laboratory research and is not naturally occurring. As with all chemicals, it should be handled with appropriate safety measures.

InChI:InChI=1/C9H10N2O/c1-11-9-5-3-2-4-7(9)8(6-12)10-11/h2-5,12H,6H2,1H3

Upstream product

• 109216-60-6 1-Methyl-1H-indazole-3-carboxylic acid methyl ester 
• 7732-18-5 water 
• 50890-83-0 1-methyl-1H-indazole-3-carboxylic acid 

Downstream Products

• 174180-57-5 1-methyl-3-bromomethyl-1H-indazole 
• 174181-81-8 N-Isopropyl-N-(4-methoxy-phenyl)-2-[3-(1-methyl-1H-indazol-3-ylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl]acetamide 
• 4002-83-9 1-methyl-1H-indazole-3-carbaldehyde 
• 1578-97-8 3-(chloromethyl)-1-methyl-1H-indazole 
• 1228935-24-7 {4-[(1-methyl-1H-indazol-3-yl)methyl]-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl}acetic acid. 
• 1228935-23-6 tert-butyl {4-[(1-methyl-1H-indazol-3-yl)methyl]-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl}acetate 
• 1228934-72-2 6-{2-[2-(2-methoxyethyl)piperidin-1-yl]-2-oxoethyl}-4-[(1-methyl-1H-indazol-3-yl)methyl]-1-phenyl-4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5(6H)-one 
• 1228934-65-3 6-{2-[(2R)-2-(3,5-dimethylbenzyl)piperidin-1-yl]-2-oxoethyl}-4-((1-methyl-1H-indazol-3-yl)methyl)-1-phenyl-4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5(6H)-one 

Relevant articles and documents

Novel rearrangement of pyrazole N imines with acetic anhydride

-

ARYL SUBSTITUTED OLEFINIC COMPOUNDS AS PDE10A INHIBITORS

The present invention provides aryl substituted olefinic compounds as Phosphodiesterase 1 0A (PDE 1 0A) inhibitors. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders by inhibiting Phospho

CCK or gastrin modulating benzo ?b!?1,4! diazepines derivatives

Benzo?b!?1,4!diazepine compounds of formula (I), where R1 is selected from C1 C6 alkyl, C3 -C6 cycloalkyl, phenyl, or substituted phenyl; R2 is selected from C3 -C6 alkyl, C3 C6 cycloalkyl, C3 -C6 alkenyl, benzyl, phenylC1 -C3 alkyl of substituted phenyl; or NR1 R2 together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C1-6 alkyl C1-6 alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R3, R5, and R6 are independently hydrogen or C1-6 alkyl; R4 is C1-6 alkyl or C1-6 alkenyl; R7 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 cycloalkyl, C1-6 alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR6 R7 together form a saturated 5,6, or 7 membered ring optionally interrupted by 1,2,3 or 4 N, S or O heteroatoms, with the proviso that any two O or S atoms are not bonded to each other, m is an integer selected from the group of 0, 1, 2, 3 or 4; R8 and R9 are selected from a variety of substituents; Z is hydrogen or halogen; novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).